Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/20/2025

Statin Therapy for Secondary Prevention of Cardiovascular Events

Evidence Supporting Statins for Secondary Prevention

  • The American College of Cardiology recommends high-intensity statin therapy for all patients with established atherosclerotic cardiovascular disease (ASCVD) for secondary prevention, as it significantly reduces cardiovascular events, including coronary heart disease death, recurrent myocardial infarction, cerebrovascular events, coronary revascularization, and all-cause mortality 1, 2
  • Statins inhibit the HMG-CoA reductase enzyme, reducing LDL-C by ≥50% with high-intensity regimens, and have been shown to delay coronary atherosclerosis progression and possibly induce plaque regression 1, 2
  • Each 1-mmol/L reduction in LDL-C results in approximately 21% reduction in the risk for cardiovascular disease events in patients with coronary heart disease, and 19% reduction in patients with cardiovascular disease other than coronary heart disease 3

Intensity of Statin Therapy

  • The American College of Cardiology recommends high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) for patients ≤75 years of age with established ASCVD, which produces a highly significant 15% further reduction in major vascular events compared to less intensive therapy 1, 2
  • Fixed high-intensity statin treatment (atorvastatin 80 mg) reduces cardiovascular events more than fixed lower-dose statin treatment, with a mean LDL-C of 77 mg/dL compared to 101 mg/dL 5

Special Populations

  • In adults with diabetes and coronary heart disease or other cardiovascular disease, moderate-dose statin therapy reduces cardiovascular events by approximately 20% per 1-mmol/L LDL-C reduction 3
  • High-intensity statin treatment (atorvastatin 80 mg) reduces cardiovascular events more than fixed lower-intensity statin treatment in adults ≥65 years of age with coronary heart disease, and in patients with chronic kidney disease (excluding hemodialysis) and coronary heart disease 5

Implementation and Adherence Considerations

  • Statin therapy should be initiated before discharge in patients hospitalized with acute myocardial infarction to improve compliance with therapy, with increasing levels of statin adherence inversely associated with LDL-C levels and mortality after acute coronary syndrome 2, 7

Safety Considerations

  • Despite the small increased risk of diabetes with statin use, the cardiovascular event rate reduction with statins far outweighs this risk, even for patients at highest risk for diabetes, with treatment of 255 patients with statins for 4 years resulting in one additional case of diabetes while preventing 5.4 vascular events 8